Subodh Verma

MD, FRCSC, FAHA, PhD

Scientist, Keenan Research Centre for Biomedical Science

Biography

Please note: Dr. Verma will not take students in summer 2019.

Dr. Subodh Verma is a cardiac surgeon-scientist at St. Michael’s Hospital, Professor at the University of Toronto and the Canada Research Chair in Atherosclerosis. He has been on the India Abroad Power List, recognized as one of Canada’s Top 40 under 40, and honoured with the Howard Morgan Award from the International Academy of Cardiovascular Sciences and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is a member of the Royal Society of Canada College of New Scholars, Artists and Scientists, and an inductee of the American Association of Thoracic Surgeons. Dr. Verma runs a practice that encompasses the entire spectrum of adult cardiac surgery (with a special interest in mitral valve repair and bicuspid aortopathy).

He is involved in several clinical trials and oversees a dynamic pre-clinical research laboratory that focuses on the roles of risk factors, inflammation and autophagy in cardiovascular health. His innovative research has culminated in nearly 300 peer-reviewed papers and two United States patents. Dr. Verma’s meta-analysis revealing that bypass surgery is superior to angioplasty in patients with diabetes has been used by the American College of Cardiology and the Canadian Cardiovascular Society (CCS) to shape the recommendations around the best clinical choice for revascularization procedures involving individuals with diabetes. He has contributed to the CCS guidelines for antiplatelet therapy, atrial fibrillation, dyslipidemia, peripheral arterial disease, and stable coronary artery disease; Canadian Cardiovascular Surgery Position Statement and Canadian Cardiometabolic Risk Position Paper. Dr. Verma spearheads the CARDIOLINK platform that will conduct clinical trials in atrial fibrillation, aneurysm and cerebral protection, diabetes and secondary prevention, valvular heart disease, and critical limb ischemia. He (co-)founded and (co-)chairs many regional and national educational initiatives that include the Landmark Lecture, State of the Heart Symposium, Toronto Acute Coronary Syndrome Summit, St. Michael’s Heart Valve Summit, Advances in Cardiology, Current Issues in Cardiology, and At the Heart of Diabetes programs.

 

Recent Publications

  1. Kosiborod, MN, Jhund, P, Docherty, KF, Diez, M, Petrie, MC, Verma, S et al.. Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial. Circulation. 2019; :. doi: 10.1161/CIRCULATIONAHA.119.044138. PubMed PMID:31736335 .
  2. Verma, S, Bain, SC, Buse, JB, Idorn, T, Rasmussen, S, Ørsted, DD et al.. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019; :. doi: 10.1001/jamacardio.2019.3080. PubMed PMID:31721979 .
  3. Mazer, CD, Hare, GMT, Connelly, PW, Gilbert, RE, Shehata, N, Quan, A et al.. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease. Circulation. 2019; :. doi: 10.1161/CIRCULATIONAHA.119.044235. PubMed PMID:31707794 .
  4. Bhatt, DL, Verma, S, Braunwald, E. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metab. 2019;30 (5):847-849. doi: 10.1016/j.cmet.2019.10.008. PubMed PMID:31693879 .
  5. Ribeiro, RVP, Yanagawa, B, Légaré, JF, Hassan, A, Ouzounian, M, Verma, S et al.. Clinical outcomes of mitral valve intervention in patients with mitral annular calcification: A systematic review and meta-analysis. J Card Surg. 2019; :. doi: 10.1111/jocs.14325. PubMed PMID:31692124 .
  6. Lam, CSP, Chandramouli, C, Ahooja, V, Verma, S. SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. J Am Heart Assoc. 2019;8 (20):e013389. doi: 10.1161/JAHA.119.013389. PubMed PMID:31607208 PubMed Central PMC6818035.
  7. McMurray, JJV, Solomon, SD, Inzucchi, SE, Køber, L, Kosiborod, MN, Martinez, FA et al.. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 2019; :. doi: 10.1056/NEJMoa1911303. PubMed PMID:31535829 .
  8. Hussain, MA, Al-Omran, M, Salata, K, Sivaswamy, A, Forbes, TL, Sattar, N et al.. Population-based secular trends in lower-extremity amputation for diabetes and peripheral artery disease. CMAJ. 2019;191 (35):E955-E961. doi: 10.1503/cmaj.190134. PubMed PMID:31481423 PubMed Central PMC6721859.
  9. Tang, GHL, Verma, S, Bhatt, DL. Transcatheter Aortic Valve Replacement in Low-Risk Patients. Circulation. 2019;140 (10):801-803. doi: 10.1161/CIRCULATIONAHA.119.041111. PubMed PMID:31479314 .
  10. Hess, DA, Terenzi, DC, Trac, JZ, Quan, A, Mason, T, Al-Omran, M et al.. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metab. 2019;30 (4):609-613. doi: 10.1016/j.cmet.2019.08.015. PubMed PMID:31477497 .
Search PubMed

Affiliations & Other Activities

  • Staff Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor, Department of Surgery and Pharmacology & Toxicology, University of Toronto
X